AIM ImmunoTech (AIM) said Wednesday its independent directors will now get 100% of their board compensation in the company's common shares instead of any director compensation in cash under a cash conservation plan devised by the compensation committee.
The company intends to attain important clinical benchmarks under the cash conservation plan, it added.
AIM said it will continue to disclose additional details about the conservation plan.
Shares of the company were down 1.8% in recent Wednesday trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。